You are on page 1of 24

Poly Medicure Limited

Corporate Presentation

1
DISCLAIMER

This presentation has been prepared by Poly Medicure Limited (the Company) solely for your information and may not be distributed, reproduced, or redistributed or passed on directly or
indirectly to any other person, whether within or outside your organization or firm, or published in whole or in part, for any purpose by recipients directly or indirectly to any other person. By
accessing this presentation, you agree to be bound by the following restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials. The Company may
alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any persons of such change or changes. This presentation and its contents are
confidential and may not be copied, published, reproduced or disseminated in any manner.

This presentation may contain certain forward looking statements based on the currently held beliefs and assumptions of the management of the Company which are expressed in good faith and in
their opinion, reasonable. These statements include descriptions regarding the intent, belief or current expectations of the Company or its directors and officers with respect to the results of
operations and financial condition of the Company. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from
those in such forward-looking statements as a result of various factors and assumptions which the Company believes to be reasonable in light of its operating experience in recent years. Many
factors could cause the actual results, performances, or achievements of the Company to be materially different from any future results, performances, or achievements. Significant factors that could
make a difference to the Companys operations include, but are not reasonable to, domestic and international economic conditions, changes in government regulations, tax regime and other
statutes. The Company does not undertake to revise any forward-looking statement that may be made from time to time by or on behalf of the Company.

This presentation contains certain supplemental measures of performance and liquidity that are not required by or presented in accordance with Indian GAAP, and should not be considered an
alternative to profit, operating revenue or any other performance measures derived in accordance with Indian GAAP or an alternative to cash flow from operations as a measure of liquidity of the
Company.

In no event shall the Company be responsible to any person or entity for any loss or damage, whether direct, indirect, incidental, consequential or otherwise, arising out of access or use
or dissemination of information contained in this presentation, including, but not limited to, loss of profits. No representation, warranty, guarantee or undertaking (express or implied) is
made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any estimates, targets and opinions, contained herein, and no
liability whatsoever is accepted as to any errors, omissions or misstatements contained herein and, accordingly, none of the Company, its advisors and representative and any of its or
their affiliates, officers, directors, employees or agents, and anyone acting on behalf of such persons accepts any responsibility or liability whatsoever, in negligence or otherwise, arising
directly or indirectly from this presentation or its contents or otherwise arising in connection therewith.

You must make your own assessment of the relevance, accuracy and adequacy of the information contained in this presentation and must make such independent analysis as you may
consider necessary or appropriate for such purpose. Any opinions expressed in this presentation are subject to change without notice and past performance is not indicative of future
results. By attending this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you
will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Companys business.

This presentation and its contents are not and should not be construed as a prospectus or an offer document, including as defined under the Companies Act, 2013, to the extent notified
and in force) or an offer document under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended. This presentation
is not for publication or distribution or release in any country where such distribution may lead to a breach of any law or regulatory requirement. The information contained herein does
not constitute or form part of an offer, or solicitation of an offer to purchase or subscribe, for securities for sale. The distribution of this presentation in certain jurisdictions may be
restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. None of the Companys securities may
be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration therefrom.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and
only the courts in Delhi, and no other courts, shall have jurisdiction over the same.

2
AGENDA

History & Profile Strategy & Approach Business Operations Governance &
About Our Company Market Opportunities Manufacturing Financials
Our Product Portfolio Key Differentiators Facilities Board of Directors &
Key Milestones Strategic Priorities Distribution Network Key Management
and Marketing Personnel
Key Financial
indicator Research and Awards &
Development Recognition
Corporate Social
Responsibility
Financial Snapshot
and Shareholding
Pattern

3
HISTORY & PROFILE

4
ABOUT OUR COMPANY

The Beginning
Started manufacturing activities in April
1997 at Faridabad with a vision of
providing highest quality healthcare at
affordable prices to all

The Company Today


One of the leading medical devices
manufacturers in India with dominant
position in medical consumables market
Produces over 100 different disposable
medical devices
Products sold in over 90 Countries
Over 1500 full time employee working
at different facilities
Listed at NSE and BSE with Market
Capitalization of approx. INR 2,000 cr +

5
OUR PRODUCT PORTFOLIO

Surgery & Wound


Drainage
3%
3% 2%
3%
4%
4%
Manufacturing
5% Revenue
Infusion Therapy

FY 2015
7%

Management
INR 360 Cr
69%

Blood
INFUSION THERAPY
BLOOD MANAGEMENT SYSTEMS
SURGERY AND WOUND DRAINAGE
UROLOGY
RESPIRATORY CARE

Others
CRITICAL CARE
OTHERS
DIAGNOSTIC
GASTROENTEROLOGY

Standalone FY 2015
6
SAFETY PRODUCTS

Safety I V Cannula Safety Fistula Needle

Safety OTN Sheath Dialator Safety PSV Blood Collection Set

7
KEY MILESTONES

Creating Shareholder Value

1995 1997 2002 2006 2009 2011 2014


Incorporation Starts commercial Establishes JV in Acquires 75% of China plant starts Company listed on SEZ, Jaipur plant starts
of Company production at Faridabad Egypt Safety Syringes Inc, commercial production NSE commercial production
USA

1996 2001 2004 2007 2010 2013 2015


Raises funds Expansion of New 100% EOU R&D center Successful US FDA Haridwar plant capacity SEZ, Jaipur phase
from IPO Faridabad Plant starts received Audit of 100% EOU expanded to meet II land acquired
commercial recognition by Faridabad factory domestic demand Expansion of
production DSIR First Bonus issued Land allotted by Toolroom & R&D
Haridwar plant HSIIDC at IMT center at
starts commercial Faridabad for future Faridabad begins
production expansion Share split in
Second Bonus issued ratio of 2:1

8
KEY FINANCIAL PARAMETERS
Figures In cr
Standalone Financials

Revenue EBITDA PAT


400 CAGR of 21% 100 CAGR of 26% 70 CAGR of 48%
374
91
90 61
350 60
312 80
74
300
70 50
253 43
250
60
209 52 40
200 50 46
30
40
150 24
30 19
20
100
20
50 10
10

0 0 0
FY 12 FY 13 FY 14 FY 15 FY 12 FY 13 FY 14 FY 15 FY 12 FY 13 FY 14 FY 15

Sustained Growth with improving top-line, EBITDA and bottom-line


9
KEY FINANCIAL PARAMETERS
Figures In cr
Consolidated Financials

Revenue EBITDA PAT


450 CAGR of 22% 100 CAGR of 25% 70 CAGR of 48%
92
390 62
400 90
60
80 75
350
322
70 50
300 45
260 60
250 52 40
217 50 47
200 30
40
24
150
30 19
20
100
20
10
50 10

0 0 0
FY 12 FY 13 FY 14 FY 15 FY 12 FY 13 FY 14 FY 15 FY 12 FY 13 FY 14 FY 15

Sustained Growth with improving top-line, EBITDA and bottom-line


10
STRATEGY AND APPROACH

11
MARKET OPPORTUNITIES

New regulatory
Make in India: regime Drug and
GOI has identified medical Cosmetic Amendment Bill
devices as a sunrise sector 2015:
Market Growth: GOI has recommended
High growth potential with Largely unregulated industry
promotion of manufacturing
rise in organized healthcare Once the amendment is
of medical devices in India
& increased awareness enacted, manufacturing of
in alignment with Make in
Proposed unified regulatory standard quality products will
Affordability: India strategy
body that can expeditiously Company believes that it is become mandatory and the
Draft National Health Company believes it is
approve introduction of well positioned to emerge
Policy envisioning uniquely positioned to quickly
new products in the market as a preferred JV partner for
health for all and corner a significant market
Focus on local innovation international companies
proposing increased share from unregulated
to improve access and looking to strengthen their
spend on healthcare players
affordability position in India with the
Increased penetration
of health insurance introduction of 100% FDI in
medical devices sector

12
KEY DIFFERENTIATORS
Diversified Product Portfolio
More than 100 products covering varied therapeutic segments
Wide geographical diversification (70% of revenues generated through exports to 90+
countries)

Innovation Capability
Over 95 patents granted and another 280+ patents filed across many countries globally
Successfully defended IPs against MNC in Europe

Manufacturing Competence
4 manufacturing facilities in India (including 1 US FDA Audited) and 1 in China
More than 50% of the export business generated from highly regulated markets

Demonstrated Growth & Profitability


Consolidated Revenues have grown at a CAGR of 22% from FY 12 to FY 15 with current year EBITDA
margin of 24%
Consolidated PAT has grown at a CAGR of 48% from FY 12 to FY 15 leading to a sustainable RoE of
20%+

Experienced Management
Strong management with experience in Innovation, Product Development and Manufacturing
Senior management has representation on prominent industry bodies (MD of the company is
Chairman, CII Medical Devices Division and Co-Chairman of PHDCCI Health Committee)

13
STRATEGIC PRIORITIES

Supplement organic growth Introducing new products in


through strategic acquisitions identified verticals in critical
and JVs enhance technical care segment
know how and distribution Expanding product basket in
reach Inorganic Growth existing verticals

Expansion of
Product Portfolio

Increasing R&D spend to Increased focus on domestic


create an innovative product market through network
Focus on
pipeline expansion and increasing
Innovation
Increased interface with key hospital outreach
Accelerating
opinion leaders to enhance Domestic Leading various Continued
knowledge in new verticals Market Reach Medical Education Programs
(CMEs) for spreading
awareness

Expanding
Plans to expand Manufacturing
manufacturing capacity to Accelerating
Capabilities
tap the domestic growth Product
Registrations Increasing product
potential by introducing
registrations in international
import substitute products
markets
Emerge as a formidable
Augmenting international
player in the organized
sales network
medical devices segment

14
BUSINESS AND OPERATIONS

15
MANUFACTURING FACILITIES

5 Manufacturing Plants with additional land


acquired for future expansion
Faridabad (2 facilities) and 1 each in
Haridwar and Jaipur
One facility in China (wholly owned
subsidiary)
State of the art facilities with capacity to
expand rapidly
All Manufacturing facilities are certified by
EU (CE Certification) ; one facility USFDA
Audited

16
DISTRIBUTION NETWORK AND MARKETING *

CMEs
Distribution Network

20+ Super Distributors 10+ Authorized Agents 1000+ Dealers

Marketing
In house Product
3000+hospitals under Over 75 CMEs conducted
Management Team and
coverage per month
nurses leading CMEs

Global Association
Tie-ups with key distributors across
Dedicated Overseas Sales Network
countries

Sales and Marketing Team

150+ Sales and Marketing Staff

* As on 31st May 2015

17
RESEARCH & DEVELOPMENT

R & D facility approved by Ministry of


Science & Technology, GOI

15 Engineers in new product development


/design

15 Engineers in value-engineering,
operational excellence and automation

Over 95 patents granted and 280+ patents


filed

18
GOVERNANCE AND FINANCIALS

19
KEY MANAGEMENT PERSONNEL

Board of Directors Key Management Personnel

Mr. Vishal Baid,


Mr. D R Mehta Mr. V. K. Khera,
President - Corporate
(Independent Director and Chairman ) SVP - Exports
Sales & Marketing

Mr. Jugal Kishore Baid Mr. Prakash Chand Mr. Deepak Gupta,
Mr. J. K. Oswal,
Surana SVP HR &
(Non Executive Vice President - Finance
(Non Executive Operational
Director) & CFO
Independent Director) Excellence

Dr. Sohan Raj Mohnot Mr. Yeshwant Singh


Mr. Hemant Bhalla,
Choudhary Mr. Avinash Chandra,
(Non Executive AVP - Sales &
(Non Executive Company Secretary
Independent Director) Marketing
Independent Director)

Dr. Shailendra Raj


Mehta Mrs. Mukulika Baid
(Non Executive (Non Executive Director)
Independent Director)

Mr. Himanshu Baid, Mr. Rishi Baid,


(Managing Director) (Executive Director)
20
AWARDS AND RECOGNITION
Silver Patent Award by Pharmaceuticals Export
Promotion Council in the Year 2009-10 for
Medical Devices Patents Category
Silver Patent Award by Pharmaceuticals Export
Promotion Council in the Year 2010-11 in
Innovation recognition of contribution to R&D in Medical
Devices Sector

Silver Patent Award by Pharmaceuticals Export


Promotion Council in the Year 2011-12 for
Medical Devices Surgical Diagnostics Category

Gold Award by Pharmaceuticals Export Promotion


Council in the Year 2010-11 for commendable
contribution to pharmaceutical sector
Top exporter award by the Plastics Export
Export Promotion Council, Govt of India in Medical
Disposables segment in the Year 2011-12
Top exporter award by the Plastics Export
Promotion Council, Govt of India in surgical items
segment in the Year 2012-13

21
CORPORATE SOCIAL RESPONSIBILITY
Supporting Education and Socio Cultural activities
Promoting education for visually & mentally challenged
children
Providing safe drinking water and toilets facility for girl
child in schools
Supporting various NGOs including Jaipur Foot involved
in upliftment of physically challenged persons
Relief supplies in Disaster prone Areas

The Akshaya Patra Foundation recognized &


appreciated the contribution of promoter director
Mr. J.K. Baid for supporting mid-day meal scheme in
schools. He was honored by Mr. Bill Clinton, Former
President of United States of America, for the above
contribution (July 2014)

22
FINANCIAL SNAPSHOT & SHAREHOLDING PATTERN
Figures In cr

For the period ended 31st March Shareholding Pattern


Particulars
2012 2013 2014 2015 (as on March 31, 2015)
Revenue From
217 260 322 390
Operations (Net)
Shareholding of Promoter and Promoter Group
EBITDA 47 52 75 92
Indian 48.37%
EBITDA Margin 22% 20% 23% 23%
Foreign 0.26%
Net Profit 19 24 45 62
Total 48.63%
Consolidated Balance Sheet Summary
As on 31st March Public Shareholding
Particulars
2012 2013 2014 2015 Institution 7.17%
Shareholder Funds 94 112 146 196 Non Institution 44.20%
Long term loans 18 24 39 40 Total 51.37%
Short term loans 1 16 13 10 21

Gross Fixed Assets 143 165 220 271

Current Assets 81 94 120 160


1includes current maturities of long term loan
Current Liabilities 2 61 68 89 112 2excludes current maturities of long term loan
All figures are rounded off
23
Thank You

24